Introduction
Sildenafil,1-{[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo [4,3-d] pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]}-4-methylpiperazine (SLD), popularly known as Viagra, is a novel oral agent for the treatment of penile erectile dysfuntion, which consists of an inability to achieve or maintain a hard, erect penis sufficient for sexual intercourse. 1, 2 It is an active inhibitor of the type V-cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase on penile erectile activity, and causes cGMP to accumulate corpus cavernosum. [3] [4] [5] [6] The clinical trails involving pharmacokinetic, efficacy and safety evaluations have revealed that SLD is an effective and well-tolerated drug in the treatment of male erectile dysfuntion. 7 Its synthesis 8 involves several steps, in which 4-amino 1-methyl-3-propylpyrazole-5-carboxamide (AMP) is initially obtained from 1-methyl-4-nitro-3-propylpyrazole-5-carboxamide (MNC) by reduction with SnCl2 under refluxed conditions. It is then condensed with 2-ethoxybenzoyl chloride and oxidized with H2O2 to yield 5-(2-ethoxyphenyl)-1-methyl-3-propyl-6,7-dihydro-1H-pyrazolo- [4,3-d] pyrimidin-7-one (EMP), which is then sulfonated with chlorosulfonic acid to give 5-[5-(chlorosulfonyl)-2-ethoxyphenyl]-1-methyl-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d ]-pyrimidon-7-one (CMP). In the last step, CMP is reacted with methyl piperazine to produce sildenafil (SLD), which is generally converted into citrate and used for treatment without further purification. 9 Since it is intended for oral consumption, its purity and safety can be thoroughly ensured before using it in different formulations. Its quality depends not only on the adopted procedures, but also on the synthetic precursors, side reaction products, unreacted raw materials, and intermediates, since they may possess unwanted toxicological effects due to which the benefit from administration of SLD may be outweighed.
Therefore, a close monitoring of related substances is of great importance for controlling the quality of SLD in the final products. A thorough literature search has indicated that the voltammetric behavior of SLD using squarewave and adsorptive stripping techniques in pharmaceutical preparations was studied. 10 A flow injection analysis (FIA) method using UV detection for the determination of SLD in pharmaceutical preparations was reported. 11 However, these methods were found not to be suitable for differentiating the related substances from SLD due to a lack of selectivity. Thus, HPLC is the technique of choice for the separation and determination of related impurities in pharmaceutical preparations. A few methods based on HPLC were reported for the determination of sildenafil citrate in biological and pharmaceutical products. A reversed-phase HPLC method using acetonitrile-phosphate buffer-water (28:4:68 v/v/v) with detection at 230 nm was utilized for the simultaneous determination of sildenafil and its metabolite (UK-103, 320) using the automated sequential trace enrichment of dialysates. 12 This method was found to be selective and precise, but not stable, thus indicating that most of the impurities have short retention times close to that of the solvent front, and not resolved from each other. Segall et al. have proposed a reversed-phase HPLC method using 70 mM potassium phosphate monobasic buffer of pH 3.0 containing 100 mM triethylamine:acetonitrile (7:3 v/v) as the mobile phase at 225 nm for the separation and determination of the degradation products of sildenafil citrate formed due to oxidation. 13 A simple and rapid high-performance liquid chromatographic method for the separation and determination of processrelated impurities of sildenafil was developed. The separation was achieved on a reversed-phase C18 column using acetonitrile-0.05 M potassium dihydrogen orthophosphate (70:30 v/v) as a mobile solvent at a flow rate of 1.0 ml/min and UV detection at 230 nm. The method was used not only for quality assurance, but also for monitoring the chemical reactions during the synthesis of sildenafil. It was found to be specific, precise and reliable for the determination of all process-related impurities of sildenafil in bulk drugs and formulations.
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Lichrospher C18 column with water-acetonitrile as the mobile phase and UV detection at 245 nm. 14 A reversed-phase HPLC method for the determination of its related substances in commercial formulations and tablets was reported. 15 However, it did not attempt to separate 1-methyl-4-nitro-3-propylpyrazole-5-carboxylic acid (MNP), which is most likely to be present as an impurity in the final products of SLD. In this paper we describe a simple and rapid reversed-phase HPLC method for the separation and determination of small amounts of all probable impurities of SLD, not only for quality assurance, but also to monitor the procedures followed during its synthesis.
Experimental
Materials and reagents Analytical reagent-grade potassium dihydrogen orthophosphate (E. Merck, Mumbai, India) and HPLC-grade acetonitrile obtained from Qualigens, Mumbai, India was used. Glass-distilled and deionized water (Nanopure, Barnsted, USA) was used throughout the study. Sildenafil and its synthetic impurities were synthesized by D. S. in his laboratory department of chemistry (Dr. Hari Singh Gour University, Sagar, India) and used.
Apparatus
An HPLC system was composed of two LC-10 AT VP pumps, an SPD-M 10A VP diode array detector, an SIL-10AD VP auto injector, a DGU 12 A degasser and an SCL-10 VP system controller (all from Shimadzu, Kyoto, Japan). A reversed-phase C18 (YMC, Kyoto, Japan) column (25 cm × 4.6 mm i.d., particle size 5 µm) was used for separation. The chromatographic and integrated data were recorded using an HP-Vectra (Hewlett Packard, Waldron, Germany) computer system.
Chromatographic conditions
The mobile phase was acetonitrile-0.05 M potassium dihydrogenphosphate (70:30 v/v); before delivering into the system it was filtered through 0.45 µm PTFE filter and degassed using a vacuum. The analysis was carried out under isocratic conditions using a flow rate of 1.0 ml/min at room temperature (28˚C). Chromatograms were recorded at 230 nm using an SPD-M 10A VP diode array detector.
Analytical procedure
Samples (5 mg) were dissolved in the mobile phase (10 ml) and a 20 µl volume of each sample was injected and chromatographed under the above conditions. Synthetic mixtures containing CMP, MNP, AMP, MNC, SLD, EMP and bulk drugs were analyzed under identical conditions. The amounts of impurities were calculated from their respective peak areas. Figure 1 shows the chemical reactions generally followed in the synthesis of SLD in a bulk drug manufacturing unit. It can be seen from Fig. 1 that there are as many as six compounds, which include the starting materials and intermediates, that could be present as potential impurities in SLD. The present study was aimed at developing a chromatographic system capable of eluting and resolving SLD and its impurities originating from synthesis. In a preliminary experiment, all of these impurities and SLD were subjected to separation by reversed-phase HPLC using a YMC C18 column and acetonitrile-water as an eluent. Two compounds viz., EMP and SLD were retained on the column when the concentration of acetonitrile was kept below 40%. However, upon increasing its concentration, these two compounds were eluted, but the separation of the other compounds was found to be effected. This would most probably be due to the adsorption of these two compounds by exposed silinols on C18 material of the HPLC column. This behavior of SLD and EMP is reasonable because both compounds have basic functional groups with pKa values of 8.7 and 8.0 with a weak acidic moiety on the parent compound. In another attempt, the water was replaced by 0.05 M potassium dihydrogenphosphate, and the effect of the concentration of the organic modifier viz., acetonitrile upon separation was studied (Fig. 2) . When the concentration of acetonitrile was at 70%, all of the impurities and SLD were eluted and separated from one another. The typical chromatogram of a synthetic mixture containing SLD and its impurities is shown in Fig. 3 . The peaks were identified by injecting and comparing with the retention times of the individual compounds. It can be seen from Fig. 3 that SLD was well separated from all of the impurities examined in the present study, and that these impurities were also well separated from each other. The specificity of the method was checked by subjecting the bulk drug under UV light at 254 nm and to stress conditions, like 0.1 M HCl, 0.1 M NaOH and 3% H2O2 solutions at 60˚C and for 24 h. All of the degraded products were found to be well-separated from SLD, and did not interfere with any of the process impurities, indicating that the method is quite specific. The chromatographic data, including the retention times (tR), retention factors (k), number of theoretical plates (N), tailing factors (Tf), relative response factors (RRF) and wavelength of absorption maxima (λmax), are given in Table  1 .
Results and Discussion
A synthetic mixture containing small quantities of impurities viz., MNP, MNC, AMP, CMP, EMP and SLD, was prepared and chromatographed to check that these quantities were accurately reflected in their peak areas. All of the estimations were carried out thrice and the percentage of error was calculated ( Table 2 ). The precision of the method was determined on 10 replicate injections of SLD solution, and reported as the relative standard deviation (RSD), 0.89%. The signal-to-noise ratio was determined to be 4.0 for the detection of impurities as low as 0.02 × 10 -9 g. It can be seen from Table  2 that the measured amounts agree well with the actual values; the mean recovery of SLD from authentic samples was found to be 99.75 ± 0.25%. The UV detector was set at 230 nm for both detection and quantification. The wavelength was selected based on observations that the resolution between the chromatographic peaks of SLD and its synthetic impurities were better.
A bulk drug of SLD was spiked with low-level impurities and chromatographed. The chromatogram is shown in Fig. 4 . The high-level (75% -120%) linearity of SLD as well as the lowlevel (0.05% -0.5%) linearity data of impurities were determined, and are recorded in Table 3 . Good linearity was found between the mass and the integral response for each of the compounds under examination. Table 3 gives the linearity equation, mass range and correlation coefficients for all of the compounds. At 0.001 A.U.F.S., the limit of detection (LOD) of SLD was 6.00 × 10 -9 g; the impurities are recorded in Table 3 . The robustness of the method was evaluated by a deliberate slight variation of the parameters, such as the mobile-phase composition, strength of potassium dihydrogenphosphate, temperature, flow rate and wavelength of absorption for detection.
No significant change was observed in the chromatographic results of SLD and its impurities, even after changing the experimental parameters.
The quality of SLD in bulk drugs was thoroughly checked. A typical chromatogram (T0h) of a bulk drug of SLD is shown in 1009 ANALYTICAL SCIENCES JULY 2003, VOL. 19 Table 4 . To determine the stability of SLD in the mobile phase, the drug was stored in the mobile phase for 24 h and chromatographed on the following day. The chromatogram is shown in Fig. 5 . It can be seen from the chromatograms of Fig.  5 , T0h and T24h that no significant change was observed. From these results, it is clear that the method is precise and accurate for the separation and determination of small quantities of some of the process impurities that are generally present in SLD.
Conclusion
A robust and sensitive HPLC procedure has been developed for the rapid determination of SLD and its synthetic impurities viz., MNP, MNC, AMP, CMP and EMP. The developed HPLC method is suitable not only for the separation and determination of process impurities, but also for monitoring the synthetic process of SLD. The method is thus suitable for the process development and quality assurance of SLD and related products. Fig. 5 Typical chromatogram of bulk drug of SLD (20 µg) stored in the mobile phase at ambient conditions for 0 h (T0h) and 24 h (T24h). For peak identification see Fig. 3 . 
